• 1. Fatty acid positional distribution in colostrum and mature milk of women living in Inner Mongolia, North Jiangsu and Guangxi of China?
  Long Deng,Qian Zou,Biao Liu,Wenhui Ye,Chengfei Zhuo,Li Chen,Ze-Yuan Deng,Ya-Wei Fan,Jing Li Food Funct., 2018,9, 4234-4245
• 2. Examination of deposit in commercial diluted phosphoric acid
  Analyst, 1880,5, 146-147
• 3. Evolution of dealloying induced strain in nanoporous gold crystals?
  Ross Harder,David C. Dunand,Ian McNulty Nanoscale, 2017,9, 5686-5693
• 4. Evidence of CO2 molecule acting as an electron acceptor on a nanoporous metal–organic-framework MIL-53 or Cr3+(OH)(O2C–C6H4–CO2)?
  Alexandre Vimont,Arnaud Travert,Philippe Bazin,Jean-Claude Lavalley,Marco Daturi,Christian Serre,Gérard Férey,Sandrine Bourrelly,Philip L. Llewellyn Chem. Commun., 2007, 3291-3293
• 5. Excellent mechanical performance and enhanced dielectric properties of OBC/SiO2 elastomeric nanocomposites: effect of dispersion of the SiO2 nanoparticles?
  Xing Zhao,Lu Bai,Rui-Ying Bao,Zheng-Ying Liu,Ming-Bo Yang,Wei Yang RSC Adv., 2017,7, 46297-46305

• Solvents and Organic Chemicals Organic Compounds Organoheterocyclic compounds Diazines Hydroxypyrimidines
• Solvents and Organic Chemicals Organic Compounds Organoheterocyclic compounds Diazines Pyrimidines and pyrimidine derivatives Hydroxypyrimidines

Introduction to 2-cyclopropyl-4-methylpyrimidin-5-ol (CAS No. 73901-42-5)

2-cyclopropyl-4-methylpyrimidin-5-ol, identified by its Chemical Abstracts Service (CAS) number 73901-42-5, is a significant heterocyclic compound that has garnered considerable attention in the field of pharmaceutical chemistry and medicinal research. This compound belongs to the pyrimidine class, a structural motif widely recognized for its biological activity and therapeutic potential. The presence of a cyclopropyl substituent and a methyl group at the 4-position of the pyrimidine ring introduces unique electronic and steric properties, making it a valuable scaffold for drug discovery and development.

The 2-cyclopropyl-4-methylpyrimidin-5-ol structure exhibits notable physicochemical characteristics, including solubility, stability, and metabolic profiles, which are critical factors in determining its suitability for pharmaceutical applications. The cyclopropyl group, in particular, is known to enhance binding affinity and selectivity by introducing conformational constraints, while the methyl group at the 4-position can influence electronic distribution and hydrogen bonding capabilities. These features make the compound an attractive candidate for further investigation in various therapeutic areas.

In recent years, there has been growing interest in pyrimidine derivatives as pharmacological agents due to their diverse biological activities. Studies have demonstrated that compounds with similar structural motifs exhibit properties such as kinase inhibition, antiviral effects, and anti-inflammatory actions. The 2-cyclopropyl-4-methylpyrimidin-5-ol molecule has been explored in several preclinical studies as a potential lead compound for developing novel therapeutics. Its ability to interact with biological targets at the molecular level has prompted researchers to investigate its mechanisms of action and potential applications in treating diseases such as cancer, infectious disorders, and metabolic conditions.

One of the most compelling aspects of 2-cyclopropyl-4-methylpyrimidin-5-ol is its versatility in chemical modification. The pyrimidine core provides multiple sites for functionalization, allowing chemists to tailor the compound’s properties for specific biological outcomes. Researchers have employed various synthetic strategies to derivatize this scaffold, resulting in a library of analogs with enhanced potency, selectivity, and pharmacokinetic profiles. These efforts have led to the identification of several promising candidates that are currently undergoing further optimization for clinical development.

The synthesis of 2-cyclopropyl-4-methylpyrimidin-5-ol typically involves multi-step organic reactions that require precise control over reaction conditions and reagent selection. Advanced synthetic methodologies, such as transition-metal-catalyzed cross-coupling reactions and palladium-mediated transformations, have been utilized to construct the desired framework efficiently. The incorporation of the cyclopropyl group often necessitates specialized techniques to ensure regioselectivity and high yields. These synthetic challenges highlight the expertise required to produce this compound in sufficient quantities for research purposes.

From a medicinal chemistry perspective, the 2-cyclopropyl-4-methylpyrimidin-5-ol molecule represents an excellent example of how structural modifications can influence biological activity. The interplay between electronic effects, steric hindrance, and hydrogen bonding interactions determines its interaction with biological targets such as enzymes and receptors. By understanding these relationships, chemists can design derivatives that exhibit improved pharmacological properties while minimizing off-target effects. This approach underscores the importance of computational modeling and experimental validation in optimizing drug candidates like 2-cyclopropyl-4-methylpyrimidin-5-ol.

The pharmacological evaluation of 2-cyclopropyl-4-methylpyrimidin-5-ol has revealed several intriguing findings. In vitro assays have shown that this compound exhibits inhibitory activity against certain kinases associated with cancer progression. Additionally, preliminary studies suggest potential benefits in modulating inflammatory pathways, making it a candidate for treating autoimmune diseases or chronic inflammatory conditions. These findings align with broader trends in drug discovery where pyrimidine-based compounds are increasingly recognized for their therapeutic value.

As research continues to advance, the applications of 2-cyclopropyl-4-methylpyrimidin-5-ol are likely to expand into new therapeutic areas. The development of novel synthetic methods and analytical techniques will further enhance our ability to study this compound’s properties and potential applications. Collaborative efforts between academia and industry are essential to translate these findings into tangible benefits for patients worldwide. The continued exploration of 2-cyclopropyl-4-methylpyrimidin-5-ol represents a testament to the ongoing innovation in pharmaceutical chemistry and medicinal biology.

The future directions for research on 2-cyclopropyl-4-methylpyrimidin-5-ol include exploring its role in drug repurposing initiatives, where existing compounds are re-evaluated for new therapeutic uses. Additionally, investigating its interactions with complex biological systems using cutting-edge technologies such as CRISPR-Cas9 gene editing could provide deeper insights into its mechanisms of action. Such studies would not only contribute to our understanding of this compound but also advance our knowledge of disease pathophysiology.

In conclusion,2-cyclopropyl-4-methylpyrimidin-5-o1 (CAS No. 73901–42–5) is a structurally intriguing compound with significant potential in pharmaceutical research. Its unique combination of chemical features makes it an attractive scaffold for developing novel therapeutics targeting various diseases. As scientific understanding evolves，the applications of this compound are expected to grow，driven by innovative synthetic methodologies，advances in computational biology，and collaborative interdisciplinary approaches.

• 2098070-20-1(2-(3-(Pyridin-3-yl)-1H-pyrazol-1-yl)acetimidamide)
• 2680771-01-9(4-cyclopentyl-3-{(prop-2-en-1-yloxy)carbonylamino}butanoic acid)
• 1444113-98-7(N-(3-cyanothiolan-3-yl)-2-[(2,2,2-trifluoroethyl)sulfanyl]pyridine-4-carboxamide)
• 332062-08-5(Fmoc-S-3-amino-4,4-diphenyl-butyric acid)
• 1270529-38-8(1,2,3,4,5,6-Hexahydro-[2,3]bipyridinyl-6-ol)
• 941977-17-9(N'-(3-chloro-2-methylphenyl)-N-2-(dimethylamino)-2-(naphthalen-1-yl)ethylethanediamide)
• 2138166-62-6(2,2-Difluoro-3-[methyl(2-methylbutyl)amino]propanoic acid)
• 89640-58-4(2-Iodo-4-nitrophenylhydrazine)
• 1449132-38-0(3-Fluoro-5-(2-fluoro-5-methylbenzylcarbamoyl)benzeneboronic acid)
• 2034271-14-0(2-(1H-indol-3-yl)-N-{[6-(thiophen-2-yl)-[1,2,4]triazolo[4,3-b]pyridazin-3-yl]methyl}acetamide)